Drug Profile
Research programme: inflammatory bowel diseases therapeutic - Cyclo Therapeutics/Janssen Biotech
Latest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Applied Molecular Transport
- Developer Cyclo Therapeutics; Janssen Biotech
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 27 Dec 2023 Applied Molecular Transport has merged with Cyclo Therapeutics to form Cyclo Therapeutics
- 28 Feb 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (PO)
- 28 Jan 2015 Drug candidate to be used for the treatment of inflmmatory bowel disease licensed to Janssen Biotech worldwide